Jul 05, 2022

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg PETACH TIKVA, Israel , July 05, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that
Jun 15, 2022

PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections

PETACH TIKVA, Israel , June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader (“KOL”) webinar on the cost of managing surgical site
Jun 06, 2022

PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

Phase 2 clinical data on the efficacy of D-PLEX 100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation PETACH TIKVA, Israel , June 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage
Jun 02, 2022

PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference , which is being held in
Jun 01, 2022

PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

Locally Administered Docetaxel Through Extended-Release Delivery via the Company’s PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel , June 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma
May 31, 2022

PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients Targeted Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 PETACH TIKVA, Israel , May
May 23, 2022

PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1 2023 • Conference Call Scheduled for Today at 8:30 a.m.
May 11, 2022

PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

•  Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX 100   in Abdominal   Soft Tissue   Surgery Expected to Occur Imminently •  Recruitment Progressing as Planned with A pproximately   900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Soft Tissue
Apr 27, 2022

PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022

PETACH TIKVA, Israel, April 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2022 financial results and operational highlights before the
Apr 25, 2022

PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

Presentation evaluates the effect of D-PLEX 100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal surgery patients PETACH TIKVA, Israel , April 25, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to
Displaying 1 - 10 of 19

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >